Id: acc0518
Group: 1sens
Protein: beta-catenin
Gene Symbol: CTNNB1
Protein Id: P35222
Protein Name: CTNB1_HUMAN
PTM: phosphorylation
Site: Ser45
Site Sequence: HSGATTTAPSLSGKGNPEEED
Disease Category: Cancer
Disease: Thyroid Cancer
Disease Subtype: anaplastic thyroid carcinoma
Disease Cellline: SW1736
Disease Info:
Drug: I131
Drug Info: "Iodine-131 (I-131) is a radioactive isotope used as a therapeutic agent for hyperthyroidism and thyroid cancer, functioning by emitting beta radiation to selectively destroy overactive thyroid cells or malignant thyroid tissue, with a physical half-life of approximately 8 days and administered orally or intravenously as a radiopharmaceutical. "
Effect: inhibit
Effect Info: "ATRA treatment reduced the phosphorylation of beta - catenin (Ser45 and Y654) and GSK - 3beta (Ser9), thereby enhancing the sensitivity of undifferentiated thyroid cancer to isotopic therapy."
Note: Non-conventional drugs
Score: 4.5
Pubmed(PMID): 29344218
Sentence Index:
Sentence:

Sequence & Structure:

MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Withdrawn colorectal adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Recruiting cirrhosis of liver ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed acute myeloid leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed chronic myelogenous leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Terminated neoplasm ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic carcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed Malignant Pancreatic Neoplasm ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
CTNNB1-Ser45
Cancer Intensity
BRCA
COAD -0.184
HGSC -1.332
ccRCC
GBM 0.613
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.904

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 45 A Wilms tumor Phosphorylation 12239584
S 45 D Esophageal carcinoma Phosphorylation 31933784
S 45 D Head and neck squamous cell carcinoma Phosphorylation 21281788
S 45 D Non-small cell lung cancer Phosphorylation 35277183
S 45 D Colon cancer Phosphorylation 32041324
S 45 N Cutaneous melanoma Phosphorylation 11351304
S 45 N Nephroblastoma Phosphorylation 12239584
S 45 N Wilms tumor Phosphorylation 12239584
S 45 N Colorectal cancer Phosphorylation 11955436

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: